UPDATE : Wednesday, July 24, 2019
상단여백
Tecentriq 1st immunotherapy to get coverage regardless of PD-L1 expression
Roche said Tecentriq, its immunotherapy treatment, will receive reimburseme...
by Lee Han-soo  |  2019-07-24 11:59
라인
Alteogen to develop growth hormone for children with Brazilian partner
Alteogen said it has signed a licensing agreement with Cristalia, a Brazili...
by Lee Han-soo  |  2019-07-23 15:57
라인
Hanmi's US partner to expand Poziotinib clinical program
Spectrum Pharmaceuticals, Hanmi Pharmaceutical's U.S. partner, said tha...
by Lee Han-soo  |  2019-07-23 14:25
라인
Merck Biopharma Korea names new general manager
Merck Korea said that it has appointed Javed Alam as the new general manage...
by Lee Han-soo  |  2019-07-23 11:08
라인
‘Doubts about biopharmaceutical-developing ability to change investment pattern’
Korea Investment & Securities said that it expects the investment sentiment...
by By Jeong Sae-im  |  2019-07-23 10:58
라인
Will Gilead enter the autoimmune diseases market?
Gilead Sciences is highly likely to buy Otezla (apremilast), a new oral PDE...
by Kim Yun-mi  |  2019-07-22 17:34
라인
Korean drugs strong in anti-reflux treatment market
Locally developed drugs are showing robust sales records in gastroesophagea...
by Jeong Sae-im  |  2019-07-22 15:15
라인
JW completes P1 trials for target anticancer treatment
JW Pharmaceuticals said that it has presented phase 1a/1b clinical trial re...
by Lee Han-soo  |  2019-07-22 14:02
라인
MedPacto passes tech assessment, seeks KOSDAQ listing this year
MedPacto, a subsidiary of Theragen Etex, is pushing be listed on the KOSDAQ...
by Jeong Sae-im  |  2019-07-19 17:01
라인
Employees file suit against Galderma Korea
Galderma Korea has recently been sued by its labor union. The company’s lab...
by Kim Yun-mi  |  2019-07-19 15:41
라인
‘Insurance benefits needed for Ibrance-fulvestrant combo treatment’
In Korea where the age of breast cancer patients is low, there is an urgent...
by Kim Yun-mi  |  2019-07-18 17:04
라인
2 cancer immunotherapy makers face different situations in reimbursement talks
Bristol-Meyers Squibb (BMS) is reportedly having a hard time persuading its...
by Kim Yun-mi  |  2019-07-18 16:01
라인
Bridge Biotherapeutics licenses out IPF treatment candidate to Boehringer
Bridge Biotherapeutics said that it has licensed out BBT-877, an idiopathic...
by Lee Han-soo  |  2019-07-18 15:58
라인
GC Labcell releases pre-clinical trial results for NK cell treatment
GC Labcell said that it has published the pre-clinical trial results for MG...
by Lee Han-soo  |  2019-07-18 14:22
라인
Sanofi vaccinates Gwangju FINA Championships staffs against hepatitis A
Sanofi Pasteur Korea said that it has vaccinated 300 staffs working for the...
by Lee Han-soo  |  2019-07-18 10:49
라인
CrystalGenomics’ US partner starts injecting leukemia treatment candidate
CrystalGenomics said Tuesday that its U.S. partner, Aptose Bioscience has i...
by Lee Han-soo  |  2019-07-17 17:45
라인
‘RIGHT Fund aims to use Korean innovation for global health equity’
Infectious diseases remain a leading cause of deaths worldwide and have bee...
by Lee Han-soo  |  2019-07-17 17:41
라인
Korean, Japanese healthcare firms reaffirm ‘joint growth’ amid trade feud
Medicine and medical equipment makers from Korea and Japan gathered to disc...
by Jeong Sae-im  |  2019-07-17 14:06
라인
RIGHT Fund reveals 1st investment into public health projects in developing countries
The Research Investment for Global Health Technology Fund, or RIGHT Fund, p...
by Lee Han-soo  |  2019-07-17 14:03
라인
'Biktarvy -- a pill a day to treat HIV'
Gilead Science Korea plans to lower the likelihood of treatment failure and...
by Lee Han-soo  |  2019-07-17 10:09
여백
여백
여백
Back to Top